HK Stock Market Move | EDDING GENOR (06998) rose nearly 2% as the IND application for GB268, a novel drug for the treatment of NSCLC and BTC, received approval from the National Medical Products Administration.
Edding Genor (06998) rose nearly 2%, up 1.91% as of press time, at HK$1.6, with a turnover of HK$256,500.
EDDING GENOR (06998) rose nearly 2%, up 1.91% as of press time at HK$1.6, with a turnover of HK$256,500.
On the news front, EDDING GENOR announced that the Company's highly differentiated and innovative PD-1/CTLA-4/VEGF trispecific antibody GB268 has received approval from China's National Medical Products Administration (NMPA) on November 12, 2026 for its Phase Ib/II investigational new drug (IND) application for monotherapy or combination therapy in the treatment of metastatic (Stage IV) non-small cell lung cancer (NSCLC), as well as its Phase II/III IND application for combined with chemotherapy as first-line treatment of locally advanced or metastatic biliary tract cancer (BTC) that is not amenable to radical surgical resection. These two developments indicate that GB268's clinical development plan has received preliminary recognition from regulatory authorities, and also mark further deepening of GB268's multi-tumor in-depth layout.
GB268 received NMPA approval for its first-in-human clinical trial in July 2025. Preliminary data from the single-agent Phase I clinical study showed that GB268 was well tolerated across the full dose range in patients with previously treated advanced solid tumors, with broad preliminary efficacy signals observed across multiple tumor types. The relevant clinical data were presented at the European Society for Medical Oncology (ESMO) Annual Congress in October 2026. In October 2026, GB268 received NMPA approval to conduct a Phase II clinical trial of combined with chemotherapy as first-line treatment for advanced colorectal cancer. GB268 is expected to conduct Phase II clinical studies in multiple solid tumors as monotherapy or in combination therapy.
Related Articles

CITIC SEC: Cost reduction and profit growth; the economic inflection point for domestic standalone energy storage is approaching.

FIN STREET SEC (01476): Chairman Zhu Yanhui is under investigation and subject to retention measures

China Securities Co.,Ltd.: AI advanced packaging drives upgrading of glass substrate materials; equipment takes the lead in the early stage of industrialization.
CITIC SEC: Cost reduction and profit growth; the economic inflection point for domestic standalone energy storage is approaching.

FIN STREET SEC (01476): Chairman Zhu Yanhui is under investigation and subject to retention measures

China Securities Co.,Ltd.: AI advanced packaging drives upgrading of glass substrate materials; equipment takes the lead in the early stage of industrialization.






